Attovia Therapeutics, Inc. · NASDAQ:ATTO
Attovia Therapeutics — Investor Presentation (September 2026)
28 slides from Attovia Therapeutics's investor presentation, September 2026
Slide 1: Shaping the future treatment of immune-mediated diseases
CO R P O R AT E P R E S E N TAT I O N · SEPTEMBER 2026 N A S D A Q : AT T O Shaping the future treatment of immune-mediated diseases
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements oth
Slide 3: Shaping the future of I&I with potential best-in-class ATTOBODY-based medicines
Shaping the future of I&I with potential best-in-class ATTOBODY -based medicines ATTO-1310, next-generation precision Pipeline enabled by validated itch therapy ATTOBODY platform • Anti-IL-31 ATTOBODY with potential for faster, • De novo precision-designed multispecifics: deeper itch relief and Q3M
Slide 4: Leadership team with board-level, transactional, and biopharma execution expertise
Leadership team with board-level, transactional, and biopharma execution expertise Tao Fu, MBA Petter Veiby Zaneta Odrowaz, Ph.D. Chief Executive Officer Chief Scientific Officer Chief Business Officer Select Prior Experience Select Prior Experience Select Prior Experience Hubert Chen, M.D. Steven C
Slide 5: Pipeline offers multiple novel assets with cross-indication opportunities
Pipeline offers multiple novel assets with cross-indication opportunities Program Target Indication(s) Discovery IND-enabling Phase 1 Phase 2 Phase 3 Anticipated Milestones Chronic Pruritus of Final Ph1b all cohorts data Unknown Origin (CPUO) 4Q26; Ph2 initiation in 1H 2027 ATTO-1310 Final Ph1b all
Slide 6: Our ATTOBODY biparatopic biologics platform is designed to enable the creation of complex biologics
Our ATTOBODY biparatopic biologics platform is designed to enable the creation of complex biologics High-potency ATTOBODY ATTO-1310 Monospecifics Fc Proprietary linker VHH1 VHH2 Modular ATTO-2306, ATTO-1091 Multispecifics Fc IgG Small size ~30kDa Conditional ATTO-006 Fc Bispecifics Epitope 1 Epitope
Slide 7: ATTO-1310: Differentiated antipruritic and initial clinical support for the ATTOBODY platform
01 ATTO-1310: Differentiated antipruritic and initial clinical support for the ATTOBODY platform
Slide 8: IL-31 is the “itch cytokine” and is elevated in a host of pruritic diseases
IL-31 is the “itch cytokine” and is elevated in a host of pruritic diseases THE BIOLOGY T H E PAT I E N T B U R D E N Loss of sleep & Immense loss of productivity; higher quality of life healthcare costs Suicidal ideation, depression Nemolizumab’s (anti-IL-31R) commercial launch success (projected $
Slide 9: ATTO-1310 is a novel IL-31 antagonist with the potential to improve pruritic disease patient care
ATTO-1310 is a novel IL-31 antagonist with the potential to improve pruritic disease patient care A T T O -1 3 1 0 T A R G E T P R O D U C T P R O F I L E Rapid itch relief via ligand targeting (Cytopoint validation) IL-31Rα blockade may direct OSMR to drive proinflammatory signaling in complex with
Slide 10: CPUO and high-itch AD are large, underserved populations with substantial unmet patient need
CPUO and high-itch AD are large, underserved populations with substantial unmet patient need CPUO High-itch AD Chronic itch lasting 6+ weeks with no identifiable Definition AD with PP-NRS 7+ cause1 U.S. Prevalence2 ~3.9M ~5.1M FDA-approved Treatment None approved No specific on-label treatments3 TCS
Slide 11: ATTO-1310 Phase 1 study design
ATTO-1310 Phase 1 study design Phase 1a: Phase 1b: Healthy Volunteer SAD / MAD Patient Cohorts2 Part 1 (n=40): Part 3 (n=26): High-Itch AD Patients (PP-NRS ≥7, EASI ≥7) Primary and secondary endpoints: • Safety SAD HV Part 4 (n=26): CP Patients (PP-NRS ≥7)3 • PK Randomized 3:1, doses: 0.5-9 mg/kg IV
Slide 12: ATTO-1310 Phase 1 healthy volunteer data demonstrate favorable tolerability
ATTO-1310 Phase 1 healthy volunteer data demonstrate favorable tolerability and support advancement to Phase 2 PK/PD Characteristics Low Immunogenicity Linear profile, approximately dose proportional 2 of 42 positive for treatment-induced ADA Rapid and sustained suppression of IL-31 No evidence of n
Slide 13: IL-31 was suppressed for at least weeks after a single dose of ATTO-1310
PRELIMINARY IL-31 was suppressed for at least 12 weeks after a single dose of ATTO- 1310 in HVs and patients with high-itch AD or CP HV SAD Cohorts HV MAD Cohorts High-itch AD and CP Patients Dose Dose Dose Dose 100 100 100 (Free/Total vs Baseline) (Free/Total vs Baseline) Percent Free IL-31 Percent
Slide 14: ATTO-1310 rapidly and deeply relieved itch in patients with chronic pruritus
PRELIMINARY ATTO-1310 rapidly and deeply relieved itch in patients with chronic pruritus Chronic Pruritus PP-NRS4 Responder Interim Analysis Chronic Pruritus PP-NRS <2 Interim Analysis Pooled 4.5 mg/kg and 9.0 mg/kg Pooled 4.5 mg/kg and 9.0 mg/kg 100% 100% ** 80% 80% PP-NRS <2 Responders (%) PP-NRS4
Slide 15: ATTO-1310 demonstrated fast and deep itch relief in patients with high-itch atopic dermatitis
PRELIMINARY ATTO-1310 demonstrated fast and deep itch relief in patients with high- itch atopic dermatitis High-itch AD PP-NRS4 Responder Interim Analysis Pooled 4.5 mg/kg and 9.0 mg/kg 100% Responders (%) 80% 60% 40% 50% 20% 44% 39% 22% 25% 25% 25% 13% 0% Week 1 Week 2 Week 3 Week 4 Placebo (n=8) A
Slide 16: ATTO-1310 Ph1b trial demonstrated promising itch relief activity vs. available competitor data
ATTO-1310 Ph1b trial demonstrated promising itch relief activity vs. available competitor data Summary of PP-NRS4 response rate (Week 4)* CPUO High-itch AD ATTO-13101 65% ATTO-13101 44% Dupilumab2 18% Nemolizumab3 28% Nemolizumab Data not available Dupilumab4 19%** Remibrutinib Data not available Le
Slide 17: Consistent lesion control observed in high-itch AD
PRELIMINARY Consistent lesion control observed in high-itch AD High-itch AD EASI % CFB (Week 4) High-itch AD EASI Responders (Week 4) Pooled 4.5 mg/kg and 9.0 mg/kg Pooled 4.5 mg/kg and 9.0 mg/kg 100% 75% Mean Percent Change from Baseline (SE) 75% 50% Responders (%) * 50% 25% 50% 25% 56% 28% 22% 17%
Slide 18: ATTO-1310 clinical development plan
ATTO-1310 clinical development plan K E Y VA LU E D R I V E R S C O M P L E T E D ST U D I E S ✓ Phase 1a: HV SAD/MAD Phase 2: CPUO Phase 2: High-itch AD ✓ Phase 1b: High-itch AD Initiation expected in 1H 2027 Initiation expected in 1H 2027 ✓ Phase 1b: Chronic pruritus 100+ subjects studied in Phase
Slide 19: ATTO-1310 can drive significant near-term and long-term value
ATTO-1310 can drive significant near-term and long-term value Large, underserved chronic itch market 01 15M+ U.S. patients $11B+ base case peak U.S. sales potential Strong clinical profile supporting late development 02 Favorable tolerability, PK/PD, and immunogenicity Encouraging early clinical act
Slide 20: ATTO-2306: Novel biotherapeutic for inflammatory skin diseases
02 ATTO-2306: Novel biotherapeutic for inflammatory skin diseases
Slide 21: The ideal profile of improved efficacy AND dosing vs. SOC remains elusive among existing AD biologics
The ideal profile of improved efficacy AND dosing vs. SOC with favorable tolerability remains elusive among existing pipeline AD biologics STANDARD OF CARE TODAY dupilumab / lebrikizumab · dosed Q2W-Q4W · partial response in many patients · well tolerated THE FUTURE STANDARD OF CARE 0 1 S U P E R I
Slide 22: ATTO-2306 (anti-IL-31 x IL-13 bispecific) target product profile
ATTO-2306 (anti-IL-31 x IL-13 bispecific) has the potential to achieve improved lesion and itch reduction with convenient dosing ATTO-2306 Target Product Profile Deeper lesion/itch reduction vs. SOC1 • Inhibits distinct complementary pathways • Highly potent anti-IL-13 and anti-IL-31 • IL-31 ligand
Slide 23: ATTO-2306 offers attractive preclinical properties and efficient path to first-in-human
ATTO-2306 offers attractive preclinical properties and efficient path to first-in-human Anti-IL-31 ATTOBODY Molecule Attributes High affinity High potency against IL-31 and IL-13, retained in bispecific Long NHP terminal half-life: ~22 days Feasibility for high-concentration SC formulation HLE YTE,
Slide 24: ATTO-1091: Next-generation trispecific for IBD
03 ATTO-1091: Next-generation trispecific for IBD
Slide 25: ATTO-1091 is a next-generation trispecific therapeutic for IBD
ATTO-1091 is a next-generation trispecific therapeutic for IBD with the potential to inhibit three clinically validated pathways Anti-IL-23 TL1A Anti-integrin Higher potency than benchmarks1 α4β7 Binds soluble and membrane TL1A Spares decoy receptor binding Blocks monomer and trimer Avoids high mole
Slide 26: Anticipated milestones
is Attovia 04 Anticipated milestones
Slide 27: Anticipated milestones
Anticipated milestones Program Target 2H’26 1H’27 2H’27 Ph1a (HV) + Ph1b All Cohorts (CP; High-itch AD) Final Data Ph1b (Cholestatic Pruritus - China) Final Readout ATTO-1310 IL-31 Ph2 (CPUO - Global) Ph2a/b (High-itch AD) ATTO-2306 Interim Readout Ph1a (HV) IL-31 x IL-13 and Ph2 Decision ATTO-1091
Slide 28: Slide 28
Attovia Therapeutics — Investor Presentation (September 2026) on 6ix